Transcriptional silencing induced by hypermethylation of CpG islands in the promoter regions of genes is believed to be an important mechanism of carcinogenesis in human cancers including gastric cancer. A number of reports on methylation of various genes in gastric cancer have been published, but most of these studies focused on cancer tissues or only a single gene. In this study, we determined the promoter hypermethylation status and mRNA expression of 4 genes: p16, Runx3, DAPK and CHFR.
Methods
Methylation-specific polymerase chain reaction (MSP) was used to determine the methylation status of p16, Runx3, DAPK and CHFR gene promoters in cancer and adjacent normal gastric mucosa specimens from 70 patients with gastric cancer, as well as normal gastric biopsy samples from 30 people without cancer serving as controls. In addition, the mRNA expression of p16, Runx3, DAPK and CHFR was investigated in 34 gastric cancer patients by RT-PCR. Bisulfite DNA sequence analysis was applied to check the positive samples detected by MSP.
Results
When carcinoma specimens were compared with adjacent normal gastric mucosa samples, a significant increase in promoter methylation of p16, Runx3, DAPK and CHFR was observed, while all 30 histologically normal gastric specimens were methylation free for all 4 genes. The methylation rate of the 4 genes increased from normal stomach tissue to tumor-adjacent gastric mucosa to gastric cancer tissue. Concurrent methylation in 2 or more genes was found in 22.9% of tumor-adjacent normal gastric mucosa and 75.7% of cancer tissues. No correlation was found between hypermethylation and other clinicopathological parameters such as sex, age, and tumor location. However, the frequency of DAPK and CHFR methylation in cancer tissues was significantly associated with the extent of differentiation and lymph node metastasis (P <0.05) and the frequency of Runx3 methylation was significantly associated with tumor size (P <0.05). Weak expression and loss of expression of the 4 genes was observed in cancer tissues and was significantly associated with promoter hypermethylation (P <0.05).
Conclusions
Promoter hypermethylation of p16, Runx3, DAPK and CHFR is frequent in gastric cancer. DAPK and CHFR promoter hypermethylation may be an important help in evaluating the differentiation grade and lymph node status of gastric cancer. Weak gene expression and loss of gene expression due to promoter hypermethylation may be a cancer-specific event. Free full text available at www.tumorionline.it
PanZ., LiJ., PanX., ChenS., WangZ., LiF., QuS., ShaoR.: Methylation of the RASSF1A gene promoter in Uigur women with cervical squamous cell carcinoma. Tumori, 95: 76–80, 2009.
10.
EstellerM.: CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene, 21: 5427–5440, 2002.
11.
GengX., WangF., ZhangL., ZhangW.M.: Loss of heterozygosity combined with promoter hypermethylation, the main mechanism of human MutL homolog (hMLH1) gene inactivation in non-small cell lung cancer in a Chinese population. Tumori, 95: 488–494, 2009.
12.
SongS.H., JongH.S., ChoiH.H., KangS.H., RyuM.H., KimN.K., KimW.H., BangY.J.: Methylation of specific CpG sites in the promoter region could significantly down-regulate p16(INK4a) expression in gastric adenocarcinoma. Int J Cancer, 87: 236–240, 2000.
13.
KatzenellenbogenR.A., BaylinS.B., HermanJ.G.: Hypermethylation of the DAP-kinase CpG island is a common alteration in B-cell malignancies. Blood, 93: 4347–4353, 1999.
14.
DuY., CarlingT., FangW., PiaoZ., SheuJ.C., HuangS.: Hypermethylation in human cancers of the RIZ1 tumor suppressor gene, a member of a histone/protein methyltransferase superfamily. Cancer Res, 61: 8094–8099, 2001.
15.
SerranoM., HannonG.J., BeachD.: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature, 366: 704–707, 1993.
16.
CairnsP., MaoL., MerloA., LeeD.J., SchwabD., EbyY., TokinoK., van der RietP., BlaugrundJ.E., SidranskyD.: Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science, 265: 415–416, 1994.
17.
ScolnickD.M., HalazonetisT.D.: CHFR defines a mitotic stress checkpoint that delays entry into metaphase. Nature, 406: 430–435, 2000.
18.
CortezD., ElledgeS.J.: Conducting the mitotic symphony. Nature, 406: 354–356, 2000.
19.
LevanonD., NegreanuV., BernsteinY., Bar-AmI., AviviL., GronerY.: AML1, AML2, and AML3, the human members of the runt domain gene-family: cDNA structure, expression, and chromosomal localization. Genomics, 23: 425–432, 1994.
20.
BaeS.C., TakahashiE.I., ZhangY.W., OgawaE., ShigesadaK., NambaY., SatakeM., ItoY.: Cloning, mapping and expression of PEBP2 C, a third gene encoding the mammalian runt domain. Gene, 159: 245–248, 1995.
21.
ShimY.H., KangG.H., RoJ.Y.: Correlation of p16 hypermethylation with p16 protein loss in sporadic gastric carcinomas. Lab Invest, 80: 689–695, 2000.
22.
Schneider-StockR., RoessnerA., UllrichO.: DAP-kinase-protector or enemy in apoptotic cell death. Int J Biochem Cell Biol, 37: 1763–1767, 2005.
23.
NgC.S., ZhangJ., WanS., LeeT.W., ArifiA.A., MokT., LoD.Y., YimA.P.: Tumor p16M is a possible marker of advanced stage in non-small cell lung cancer. J Surg Oncol, 79: 101–106, 2002.
24.
MittagF., KuesterD., ViethM., PetersB., StolteB., RoessnerA., Schneider-StockR.: DAPK promoter methylation is an early event in colorectal carcinogenesis. Cancer Lett, 240: 69–75, 2006.
25.
SchildhausH.U., KrockelI., LippertH., MalfertheinerP., RoessnerA., Schneider-StockR.: Promoter hypermethylation of p16INK4a, E-cadherin, O6-MGMT, DAPK and FHIT in adenocarcinomas of the esophagus, esophagogastric junction and proximal stomach. Int J Oncol, 26: 1493–1500, 2005.
26.
HermanJ.G., BaylinS.B.: Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med, 349: 2042–2054, 2003.
27.
TangX., KhuriF.R., LeeJ.J., KempB.L., LiuD., HongW.K., MaoL.: Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer. J Natl Cancer Inst, 92: 1511–1516, 2000.
28.
HermanJ.G., GraffJ.R., MyöhänenS., NelkinB.D., BaylinSB, Methylation-specificP.C.R.: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA, 93: 9821–9826, 1996.
29.
KangG.H., LeeS., KimW.H., LeeH.W., KimJ.C., RhyuM.G., RoJ.Y.: Epstein-Barr virus-positive gastric carcinoma demonstrates frequent aberrant methylation of multiple genes and constitutes CpG island methylator phenotype–positive gastric carcinoma. Am J Pathol, 160: 787–794, 2002.
30.
SadikovicB., RodenhiserD.I.: Benzopyrene exposure disrupts DNA methylation and growth dynamics in breast cancer cells. Toxicol Appl Pharmacol, 216: 458–468, 2006.
31.
ToyotaM., AhujaN., Ohe-ToyotaM., HermanJ.G., BaylinS.B., IssaJ.P.: CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA, 96: 8681–8686, 1999.
32.
Schneider-StockR., KuesterD., UllrichO., MittagF., HaboldC., BoltzeC., PetersB., KruegerS., HintzeC., MeyerF., HartigR., RoessnerA.: Close localization of DAP-kinase positive tumor-associated macrophages and apoptotic colorectal cancer cells. J Pathol, 209: 95–105, 2006.
33.
KangY.H., BaeS.I., KimW.H.: Comprehensive analysis of promoter methylation and altered expression of hMLH1 in gastric cancer cell lines with microsatellite instability. J Cancer Res Clin Oncol, 128: 119–124, 2002.
34.
RoaJ.C., AnabalónL., RoaI., TapiaO., MeloA., VillasecaM., ArayaJ.C.: Promoter methylation profile in gastric cancer. Rev Med Chil, 133: 874–880, 2005.
35.
RoaS.J.C., GarcíaM.P., MeloA.A., TapiaE.O., VillasecaH.M., ArayaO.J.C., GuzmánG.P.: Gene methylation patterns in digestive tumors. Rev Med Chil, 136: 451–458, 2008.
36.
SuzukiH., ItohF., ToyotaM., KikuchiT., KakiuchiH., HinodaY., ImaiK.: Distinct methylation pattern and microsatellite instability in sporadic gastric cancer. Int J Cancer, 83: 309–313, 1999.
37.
ToyotaM., AhujaN., SuzukiH., ItohF., Ohe-ToyotaM., ImaiK., BaylinS.B., IssaJ.P.: Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res, 59: 5438–5442, 1999.
38.
ShimY.H., KangG.H., RoJ.Y.: Correlation of p16 hypermethylation with p16 protein loss in sporadic gastric carcinomas. Lab Invest, 80: 689–695, 2000.
39.
GaoN., ChenW.C., CenJ.N.: Relationship between RUNX3 gene expression and its DNA methylation in gastric cancer. Zhonghua Zhong Liu Za Zhi, 30: 361–364, 2008.
40.
KimT.Y., LeeH.J., HwangK.S., LeeM., KimJ.W., BangY.J., KangG.H.: Methylation of RUNX3 in various types of human cancers and premalignant stages of gastric carcinoma. Lab Invest, 84: 479–484, 2004.
41.
GarganoG., CalcaraD., CorsaleS., AgneseV., IntriviciC., FulfaroF., PantusoG., CajozzoM., MorelloV, TomasinoR.M., OttiniL., ColucciG., BazanV., RussoA.: Aberrant methylation within RUNX3 CpG island associated with the nuclear and mitochondrial microsatellite instability in sporadic gastric cancers. Results of a GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study. Ann Oncol, 18: 103–109, 2007.
42.
SabbioniS., MiottoE., VeroneseA., SattinE., GramantieriL., BolondiL., CalinG.A., GafàR., LanzaG., CarliG., FerrazziE., FeoC., LiboniA., GulliniS., NegriniM.: Multigene methylation analysis of gastrointestinal tumors: TPEF emerges as a frequent tumor-specific aberrantly methylated marker that can be detected in peripheral blood. Mol Diagn, 7: 201–207, 2003.
43.
KimW.S., SonH.J., ParkJ.O., SongS.Y., ParkC.: Promoter methylation and down-regulation of DAPK is associated with gastric atrophy. Int J Mol Med, 12: 827–830, 2003.
44.
SchildhausH.U., KröckelI., LippertH., MalfertheinerP., RoessnerA., Schneider-StockR.: Promoter hypermethylation of p16INK4a, E-cadherin, O6-MGMT, DAPK and FHIT in adenocarcinomas of the esophagus, esophagogastric junction and proximal stomach. Int J Oncol, 26: 1493–1500, 2005.
45.
WakiT., TamuraG., SatoM., TerashimaM., NishizukaS., MotoyamaT.: Promoter methylation status of DAP-kinase and RUNX3 genes in neoplastic and non-neoplastic gastric epithelia. Cancer Sci, 94: 360–364, 2003.
46.
TangL.P., ChoC.H., HuiW.M., HuangC., ChuK.M., XiaH.H., LamS.K., RashidA., WongB.C., ChanA.O.: An inverse correlation between interleukin-6 and select gene promoter methylation in patients with gastric cancer. Digestion, 74: 85–90, 2006.
47.
ChangM.S., UozakiH., ChongJ.M., UshikuT., SakumaK., IshikawaS., HinoR., BaruaR.R., IwasakiY., AraiK., FujiiH., NagaiH., FukayamaM.: CpG island methylation status in gastric carcinoma with and without infection of Epstein-Barr virus. Clin Cancer Res, 12: 2995–3002, 2006.
48.
MoriokaY., HibiK., SakaiM., KoikeM., FujiwaraM., KoderaY., ItoK., NakaoA.: Aberrant methylation of the CHFR gene in digestive tract cancer. Anticancer Res, 26: 1791–1795, 2006.
49.
KogaY., KitajimaY., MiyoshiA., SatoK., SatoS., MiyazakiK.: The significance of aberrant CHFR methylation for clinical response to microtubule inhibitors in gastric cancer. J Gastroenterol, 41: 133–139, 2006.
50.
GaoY.J., XinY., ZhangJ.J., ZhouJ.: Mechanism and pathobiologic implications of CHFR promoter methylation in gastric carcinoma. World J Gastroenterol, 14: 5000–5007, 2008.
51.
OkiE., ZhaoY., YoshidaR., MasudaT., AndoK., SugiyamaM., TokunagaE., MoritaM., KakejiY., MaeharaY.: Checkpoint with forkhead-associated and ring finger promoter hypermethylation correlates with microsatellite instability in gastric cancer. World J Gastroenterol, 15: 2520–2525, 2009.
52.
KatoK., IidaS., UetakeH., TakagiY., YamashitaT., InokuchiM., YamadaH., KojimaK., SugiharaK.: Methylated TMS1 and DAPK genes predict prognosis and response to chemotherapy in gastric cancer. Int J Cancer, 122: 603–608, 2008.
